192 related articles for article (PubMed ID: 34155503)
1. The Interpretation of Sequence Variants in Myeloid Neoplasms.
Hanbazazh M; Harada S; Reddy V; Mackinnon AC; Harbi D; Morlote D
Am J Clin Pathol; 2021 Oct; 156(5):728-748. PubMed ID: 34155503
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
3. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
4. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
Northrup V; Maybank A; Carson N; Rahmeh T
Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
6. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
[No Abstract] [Full Text] [Related]
7. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
[TBL] [Abstract][Full Text] [Related]
8. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
9. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
10. Applications of next-generation sequencing in hematologic malignancies.
Ramkissoon LA; Montgomery ND
Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
[TBL] [Abstract][Full Text] [Related]
11. Genomic testing in myeloid malignancy.
Docking TR; Karsan A
Int J Lab Hematol; 2019 May; 41 Suppl 1():117-125. PubMed ID: 31069982
[TBL] [Abstract][Full Text] [Related]
12. How I diagnose myeloid neoplasms with germline predisposition.
Patel N; Calvo KR
Am J Clin Pathol; 2023 Oct; 160(4):352-364. PubMed ID: 37458302
[TBL] [Abstract][Full Text] [Related]
13. Internal Standardization of the Interpretation and Reporting of Sequence Variants in Hematologic Neoplasms.
Mehta N; He R; Viswanatha DS
Mol Diagn Ther; 2021 Jul; 25(4):517-526. PubMed ID: 34125426
[TBL] [Abstract][Full Text] [Related]
14. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
Kuo FC
Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973
[TBL] [Abstract][Full Text] [Related]
16. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.
Ok CY; Leventaki V; Wang SA; Dinardo C; Medeiros LJ; Konoplev S
Am J Clin Pathol; 2016 Feb; 145(2):271-6. PubMed ID: 26800764
[TBL] [Abstract][Full Text] [Related]
17. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
18. Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis.
Karner K; George TI; Patel JL
Ann Lab Med; 2019 Nov; 39(6):509-514. PubMed ID: 31240877
[TBL] [Abstract][Full Text] [Related]
19. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing.
Shen W; Paxton CN; Szankasi P; Longhurst M; Schumacher JA; Frizzell KA; Sorrells SM; Clayton AL; Jattani RP; Patel JL; Toydemir R; Kelley TW; Xu X
J Clin Pathol; 2018 Apr; 71(4):372-378. PubMed ID: 29197855
[TBL] [Abstract][Full Text] [Related]
20. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.
Kanagal-Shamanna R; Singh RR; Routbort MJ; Patel KP; Medeiros LJ; Luthra R
Expert Rev Mol Diagn; 2016; 16(4):461-72. PubMed ID: 26765348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
